Thomas Wagner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas Wagner has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
A. Julian
Nuclear Medicine Department, bInternal Medicine Department, cNeuroradiology Department, dPathology Department, Toulouse Purpan University Hospital, Place du Docteur Baylac, Toulouse, France; eNuclear Medicine Department, Royal Free Hospital, London, UK
2 shared publicationsC. Chevreau
Department of Medical Oncology, Claudius Regaud Institute, Toulouse, France
2 shared publications- Frédéric Courbon
Institut Claudius Regaud, Toulouse, France
2 shared publications N. Meyer
Department of Dermatology, Toulouse University Hospital, Paul-Sabatier University, Toulouse, France
2 shared publications- Pierre Payoux
Toulouse NeuroImaging Center (ToNIC) UMR1214 Inserm, Université de Toulouse III, Toulouse, France, Toulouse France
2 shared publications - Slimane Zerdoud
Service de médecine nucléaire, institut universitaire du cancer Toulouse Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France
2 shared publications
Latest Publications
- Open Access
- 1 January 2013
- Published by E-MED LTD in Cancer Imaging
- Vol. 13 (1) , 73-80
Therapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
Introduction: Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor prognosis. Adequate staging and therapeutic evaluation is necessary for therapy planning. Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography ...
- 1 January 2013
- Published by E-MED LTD in Cancer Imaging
- Vol. 13 (1) , 73-80
Open AccessTherapy response evaluation with FDG-PET/CT in small cell lung cancer: a prognostic and comparison study of the PERCIST and EORTC criteria
Introduction: Small cell lung cancer (SCLC) is an aggressive form of lung cancer with poor prognosis. Adequate staging and therapeutic evaluation is necessary for therapy planning. Fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography ...
- Open Access
- 1 January 2012
- Published by E-MED LTD in Cancer Imaging
- Vol. 12 (1) , 7-12
Diffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs
A 71-year-old woman was admitted to our hospital with asthenia, weight loss, fever, cognitive impairment and shortness of breath. Physical examination showed hemiparesis and cerebellar ataxia. There was no superficial lymphadenopathy. Blood tests showed ...
- 1 January 2012
- Published by E-MED LTD in Cancer Imaging
- Vol. 12 (1) , 7-12
Open AccessDiffuse pulmonary uptake on FDG-PET with normal CT diagnosed as intravascular large B-cell lymphoma: a case report and a discussion of the causes of diffuse FDG uptake in the lungs
A 71-year-old woman was admitted to our hospital with asthenia, weight loss, fever, cognitive impairment and shortness of breath. Physical examination showed hemiparesis and cerebellar ataxia. There was no superficial lymphadenopathy. Blood tests showed ...
- Open Access
- 1 December 2011
- Published by VM Media Group sp. z o.o in Nuclear Medicine Review
- Vol. 14 (2) , 109-111
A false-positive finding in therapeutic evaluation: hypermetabolic axillary lymph node in a lymphoma patient following FDG extravasation
We report a case of a false-positive finding in FDG PET/CT following radiotracer extravasation. A 15-year-old male patient was referred for therapeutic evaluation status post-chemotherapy for a lymphoblastic lymphoma. FDG PET/CT showed discordant findings with a marked decrease in a liver/hepatic hilum uptake, disappearance of a subcutaneous left supraclavicular uptake, and appearance of intense right axillary nodal uptake. Extravasation in the right superior limb was noted. Comparison with the previous scan showed that the axillary nodes were present, measured less than 1 cm in their short axis, had not increased in size, and had a fatty hilum. We concluded that FDG uptake was caused by a migration in lymphatic vessels.
- 1 December 2011
- Published by VM Media Group sp. z o.o in Nuclear Medicine Review
- Vol. 14 (2) , 109-111
Open AccessA false-positive finding in therapeutic evaluation: hypermetabolic axillary lymph node in a lymphoma patient following FDG extravasation
We report a case of a false-positive finding in FDG PET/CT following radiotracer extravasation. A 15-year-old male patient was referred for therapeutic evaluation status post-chemotherapy for a lymphoblastic lymphoma. FDG PET/CT showed discordant findings with a marked decrease in a liver/hepatic hilum uptake, disappearance of a subcutaneous left supraclavicular uptake, and appearance of intense right axillary nodal uptake. Extravasation in the right superior limb was noted. Comparison with the previous scan showed that the axillary nodes were present, measured less than 1 cm in their short axis, had not increased in size, and had a fatty hilum. We concluded that FDG uptake was caused by a migration in lymphatic vessels.
- 24 October 2011
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 26 (11) , 1431-1435
Routine FDG PET‐CT in patients with a high‐risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases
Background FDG PET‐CT is the superior imaging modality for the detection of visceral metastases (M+) in patients with melanoma. Conflicting evidence exists regarding its role for the initial staging of patients with high risk localized melanoma (large Breslow Thickness (BT) and/or ulceration).Objective To assess the role of routine staging with FDG PET‐CT in melanoma patients with localized high risk melanoma.Methods Forty‐eight consecutive patients with 1 < BT < 4 mm with ulceration and with BT ≥ 4 mm were staged with PET‐CT. PET‐CT procedures were performed on a GE Discovery ST® scanner. PET‐CT findings for regional nodal status and presence of distant metastatic disease were collected. The gold standard for nodal assessment was pathological examination. The gold standard for M+ was conventional imaging and clinical follow‐up, confirmed by biopsy whenever feasible.Results No patient had a positive PET‐CT for M+. Six patients (13%) had a non‐conclusive PET‐CT; none of them presented with M+ within 6 months. Forty‐three patients (90%) had a negative PET‐CT, amongst them only one patient (2.5%) presented with M+ within a year. Six patients had FDG‐avid lymph nodes in the drainage territory of the primary melanoma, either SLNB or lymph node dissection confirmed metastatic nodal involvement. The predictive positive value of PET for regional node involvement was 100%.Comments FDG PET‐CT does not seem to be effective at detecting M+ at baseline staging in patients with high risk localized melanoma. However, it has a high negative predictive value for the presence of M+ at 6 months and a high positive predictive value for nodal involvement.
- 24 October 2011
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 26 (11) , 1431-1435
Routine FDG PET‐CT in patients with a high‐risk localized melanoma has a high predictive positive value for nodal disease and high negative predictive value for the presence of distant metastases
Background FDG PET‐CT is the superior imaging modality for the detection of visceral metastases (M+) in patients with melanoma. Conflicting evidence exists regarding its role for the initial staging of patients with high risk localized melanoma (large Breslow Thickness (BT) and/or ulceration).Objective To assess the role of routine staging with FDG PET‐CT in melanoma patients with localized high risk melanoma.Methods Forty‐eight consecutive patients with 1 < BT < 4 mm with ulceration and with BT ≥ 4 mm were staged with PET‐CT. PET‐CT procedures were performed on a GE Discovery ST® scanner. PET‐CT findings for regional nodal status and presence of distant metastatic disease were collected. The gold standard for nodal assessment was pathological examination. The gold standard for M+ was conventional imaging and clinical follow‐up, confirmed by biopsy whenever feasible.Results No patient had a positive PET‐CT for M+. Six patients (13%) had a non‐conclusive PET‐CT; none of them presented with M+ within 6 months. Forty‐three patients (90%) had a negative PET‐CT, amongst them only one patient (2.5%) presented with M+ within a year. Six patients had FDG‐avid lymph nodes in the drainage territory of the primary melanoma, either SLNB or lymph node dissection confirmed metastatic nodal involvement. The predictive positive value of PET for regional node involvement was 100%.Comments FDG PET‐CT does not seem to be effective at detecting M+ at baseline staging in patients with high risk localized melanoma. However, it has a high negative predictive value for the presence of M+ at 6 months and a high positive predictive value for nodal involvement.
- 13 May 2011
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 164 (6) , 1235-1240
Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node
Positron emission tomography (PET) using fluorodeoxyglucose (FDG) has proven to be more sensitive and accurate than other imaging modalities for the detection of distant metastases in patients with melanoma. Sentinel lymph node (SLN) status is the most important prognostic factor in melanoma patients with no evidence of distant metastasis. To assess the rate of distant metastases in patients with a positive SLN biopsy (SLNB). Forty-six consecutive patients with a positive SLNB underwent PET or PET-computed tomography within 6 weeks of the SLNB procedure. The patients did not present any clinical sign of nodal involvement or of distant metastasis. PET findings were classified as positive, negative or nonconclusive. No patient had a positive PET scan for distant metastasis. Six patients (13%) had a nonconclusive PET scan; none of them presented distant metastasis within 12 months. Forty patients (87%) had a negative PET scan; among them five (12%) presented with distant metastasis within 12 months. Fluorodeoxyglucose positron emission tomography failed to detect distant metastases at initial staging in patients with a positive SLNB, even in patients who presented with distant metastases within 12 months after the FDG PET scan. These results could be explained by the low prevalence of macroscopic metastatic disease at this stage and by the important delay between the onset of the spread of microscopic metastatic disease and the identification by PET scan of macroscopic metastatic disease.
- 13 May 2011
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 164 (6) , 1235-1240
Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node
Positron emission tomography (PET) using fluorodeoxyglucose (FDG) has proven to be more sensitive and accurate than other imaging modalities for the detection of distant metastases in patients with melanoma. Sentinel lymph node (SLN) status is the most important prognostic factor in melanoma patients with no evidence of distant metastasis. To assess the rate of distant metastases in patients with a positive SLN biopsy (SLNB). Forty-six consecutive patients with a positive SLNB underwent PET or PET-computed tomography within 6 weeks of the SLNB procedure. The patients did not present any clinical sign of nodal involvement or of distant metastasis. PET findings were classified as positive, negative or nonconclusive. No patient had a positive PET scan for distant metastasis. Six patients (13%) had a nonconclusive PET scan; none of them presented distant metastasis within 12 months. Forty patients (87%) had a negative PET scan; among them five (12%) presented with distant metastasis within 12 months. Fluorodeoxyglucose positron emission tomography failed to detect distant metastases at initial staging in patients with a positive SLNB, even in patients who presented with distant metastases within 12 months after the FDG PET scan. These results could be explained by the low prevalence of macroscopic metastatic disease at this stage and by the important delay between the onset of the spread of microscopic metastatic disease and the identification by PET scan of macroscopic metastatic disease.
- 1 January 2010
- Vol. 13 (1) , 5-7
Discordance between labelled white blood cell scintigraphy and bone scan following suspicion of bone infection: what should be done about it?
Bone infection is a common issue in infectiology. The gold standard for evaluating bone infection is the white blood cell (WBC) scan. In our practice the WBC scan is coupled with a bone scan. Discordances in the results of these two examinations are a common occurrence in daily practice. We decided to investigate the meaning of these discordances. Two hundred and ninety-six 99mTc-HMPA labelled white blood cells (WBC) and 99mTc-HMDP bone scanning (BS) examinations were performed in our department between 1997 and 2003 for evaluation of bone infection. Out of these 296 examinations, a first rating extracted 54 scans that were considered discordant. These 54 scans were reviewed by three observers. Clinical and paraclinical data were obtained for all the cases definitely considered as discordant by all three observers. The observers finally retained 18 cases as discordant from the initial 296 (6.1%). Thirteen patients were not infected,and five patients were considered infected based on clinical follow-up or bacteriological and histological data. For the 17 patients with WBC-, BS+, 4 (23.5%) were infected. Our study shows that in the vast majority(17 out of 18), discordances consist of a negative WBC scan with a positive bone scan. In these cases the accuracy of the WBC scan is diminished as 23.5% of the patients with a negative WBC and a positive bone scan are infected.
- 1 January 2010
- Vol. 13 (1) , 5-7
Discordance between labelled white blood cell scintigraphy and bone scan following suspicion of bone infection: what should be done about it?
Bone infection is a common issue in infectiology. The gold standard for evaluating bone infection is the white blood cell (WBC) scan. In our practice the WBC scan is coupled with a bone scan. Discordances in the results of these two examinations are a common occurrence in daily practice. We decided to investigate the meaning of these discordances. Two hundred and ninety-six 99mTc-HMPA labelled white blood cells (WBC) and 99mTc-HMDP bone scanning (BS) examinations were performed in our department between 1997 and 2003 for evaluation of bone infection. Out of these 296 examinations, a first rating extracted 54 scans that were considered discordant. These 54 scans were reviewed by three observers. Clinical and paraclinical data were obtained for all the cases definitely considered as discordant by all three observers. The observers finally retained 18 cases as discordant from the initial 296 (6.1%). Thirteen patients were not infected,and five patients were considered infected based on clinical follow-up or bacteriological and histological data. For the 17 patients with WBC-, BS+, 4 (23.5%) were infected. Our study shows that in the vast majority(17 out of 18), discordances consist of a negative WBC scan with a positive bone scan. In these cases the accuracy of the WBC scan is diminished as 23.5% of the patients with a negative WBC and a positive bone scan are infected.